發(fā)布時(shí)間：2018-06-26 10:24

  本文選題：熱療 + 培美曲塞　； 參考：《中國(guó)藥房》2017年33期

【摘要】：目的:觀察熱療聯(lián)合培美曲塞、順鉑治療中晚期肺腺癌的療效和安全性。方法:回顧性分析120例中晚期肺腺癌患者資料,按治療方案不同分為對(duì)照組(60例)和觀察組(60例)。對(duì)照組患者給予注射用培美曲塞二鈉500 mg/m~2,靜脈滴注,d1+注射用順鉑75 mg/m~2,靜脈滴注,d2~4(分3 d使用)。21 d為1個(gè)周期,至少化療2個(gè)周期。觀察組患者在對(duì)照組化療的基礎(chǔ)上行熱療每月1次,共2~4次。觀察兩組患者的臨床療效,生活質(zhì)量改善情況及毒副反應(yīng)發(fā)生情況。結(jié)果:兩組患者至少接受2個(gè)周期治療。觀察組患者總有效率(63.3%)顯著高于對(duì)照組(36.7%),生活質(zhì)量改善率(60.0%)顯著高于對(duì)照組(33.3%),差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。兩組患者Ⅲ~Ⅳ度肝腎功能損害、骨髓抑制、消化道反應(yīng)發(fā)生率比較,差異均無統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:熱療聯(lián)合培美曲塞、順鉑治療中晚期肺腺癌的療效顯著,可提高生存質(zhì)量,且未增加嚴(yán)重毒副反應(yīng)的發(fā)生率。
[Abstract]:Objective: to observe the efficacy and safety of hyperthermia combined with pemetrexide and cisplatin in the treatment of advanced lung adenocarcinoma. Methods: 120 patients with advanced lung adenocarcinoma were retrospectively analyzed and divided into control group (n = 60) and observation group (n = 60). Patients in the control group were given pemetrexed disodium 500 mg / mm-2, cisplatin 75 mg / m-2 for intravenously infused D1, and pemetrexide for 3 days for 21 days, at least 2 cycles of chemotherapy. The patients in the observation group were treated with hyperthermia once a month on the basis of chemotherapy in the control group. To observe the clinical effect, quality of life improvement and side effects of the two groups. Results: two groups of patients received at least 2 cycles of treatment. The total effective rate (63.3%) in the observation group was significantly higher than that in the control group (36.7%), and the improvement rate of quality of life (60.0%) was significantly higher than that in the control group (33.3%), the difference was statistically significant (P0.05). There was no significant difference in the incidence of liver and kidney dysfunction, bone marrow suppression and digestive tract reaction between the two groups (P0.05). Conclusion: hyperthermia combined with pemetrexide is effective in the treatment of middle and advanced lung adenocarcinoma. It can improve the quality of life and does not increase the incidence of severe side effects.
【作者單位】： 解放軍第150中心醫(yī)院腫瘤科;
【分類號(hào)】：R734.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 趙瑩瑩;盧紹禹;杜文;梁潔;楊艷華;;變性高效液相色譜法檢測(cè)晚期肺腺癌人類表皮生長(zhǎng)因子受體2突變的探索性研究[J];中國(guó)醫(yī)學(xué)創(chuàng)新;2013年07期

2 王中奇;鄧海濱;張銘;周衛(wèi)東;吳繼;趙曉珍;王立芳;白冰;徐振曄;;中藥分階段結(jié)合化療治療晚期肺腺癌臨床研究[J];上海中醫(yī)藥雜志;2010年03期

3 王立芳;徐振曄;金長(zhǎng)娟;王中奇;鄧海濱;張銘;周衛(wèi)東;李敏;吳繼;趙曉珍;白冰;吳秋霞;;中醫(yī)藥分階段結(jié)合化療治療晚期肺腺癌臨床研究[J];上海中醫(yī)藥雜志;2010年06期

4 李春娟;王俊峰;韓為清;許娜;;晚期肺腺癌的臨床治療與分析[J];醫(yī)學(xué)信息(上旬刊);2011年01期

5 趙曉;燕翔;孫勝杰;吳志勇;焦順昌;;晚期肺腺癌患者外周血T淋巴細(xì)胞亞群檢測(cè)的臨床意義[J];南方醫(yī)科大學(xué)學(xué)報(bào);2012年05期

6 燕翔;趙曉;焦順昌;胡毅;孫勝杰;吳亮亮;吳志勇;;晚期肺腺癌患者外周血T細(xì)胞淋巴亞群的檢測(cè)及危險(xiǎn)因素評(píng)估[J];中國(guó)醫(yī)學(xué)科學(xué)院學(xué)報(bào);2012年03期

7 孫婧華;張陽(yáng);趙金波;劉芳;戴朝霞;蔣葵;馮仲珉;孫秀華;;�？颂婺嶂委�17例晚期肺腺癌非吸煙患者的早期臨床療效觀察[J];中國(guó)新藥雜志;2012年14期

8 王桂平;韋敏;廖洪映;周瓊;王妍;林竹貞;張彥燾;;早期和晚期肺腺癌的差異基因和信號(hào)通路富集分析[J];中國(guó)腫瘤;2013年01期

9 王麗;史美祺;;貝伐單抗聯(lián)合化療一線治療晚期肺腺癌的療效及安全性[J];中國(guó)腫瘤臨床與康復(fù);2013年02期

10 張潔;魯曉寧;班麗英;;鹽酸�？颂婺嶂委�50例晚期肺腺癌的臨床觀察[J];中國(guó)新藥雜志;2013年09期

相關(guān)會(huì)議論文 前10條

1 張貝貝;何春曉;宋正波;婁廣媛;余新民;趙s，

本文編號(hào)：2070067